Skip to content
AI.info

The Pulse

Isomorphic Labs raises $5 billion for AI drug design

Greenoaks and Sequoia Capital co-led Isomorphic Labs' $5 billion Series C financing round, with continued investment from Alphabet. The company plans to develop its AI drug design engine and advance medicine candidates toward clinical trials.

Isomorphic Labs raises $5 billion for AI drug design

Isomorphic Labs has raised $5 billion in a Series C financing round to develop its AI drug design technology and move medicine candidates toward clinical trials. Greenoaks and Sequoia Capital co-led the round, the company said on November 17.

Andreessen Horowitz and several other new investors joined the round, alongside continued investment from Alphabet. Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also participated; the company said all its existing investors took part.

Funding the next stage

The financing was oversubscribed, according to Isomorphic. The company plans to use the capital to develop its drug design engine further, expand its models into new areas of biology and build infrastructure for AI-led bioengineering.

Isomorphic is also creating a partner ecosystem intended to improve understanding of the mechanisms of disease. Its portfolio includes both wholly owned internal programs and work with partners.

The company was founded in 2021 and is led by founder and CEO Sir Demis Hassabis and president Max Jaderberg. Its headquarters are in London, with offices in Cambridge, Massachusetts, and Lausanne, Switzerland.

Models for drug design

Isomorphic's drug design engine, called IsoDDE, brings together predictive and generative AI models for use across biological systems, therapeutic areas and types of medicine. The company says it can generate molecule designs, predict their properties and refine them computationally before scientists decide what to make and test in a laboratory.

The company says its models work alongside proprietary agents that navigate and reason over complex biological systems. Isomorphic uses the engine across its internal and partnered programs as it develops potential medicines.

Isomorphic said it was seeing positive preclinical results in its internal oncology and immunology programs and in work with partners. Hassabis said the financing would help the company advance its first therapeutic programs toward clinical trials.

The proceeds will also support further development of the company's translational and clinical development infrastructure as it advances drug candidates toward trials. Isomorphic plans to continue developing its foundational biology models and expand its understanding of disease.

Pharmaceutical partnerships

The company lists research collaborations with Novartis, Eli Lilly and Company, and Johnson & Johnson. Its Novartis collaboration began in January 2024 and was expanded in February 2025.

The original work focused on finding small-molecule therapeutics against three targets; the expansion added up to three further research programs. The Lilly collaboration focuses on discovering small-molecule therapeutics against undisclosed targets.

The Johnson & Johnson collaboration covers multiple targets and types of medicine, including small molecules and biologics. The partners are working to identify novel molecules and develop therapeutics for diseases that have been difficult to address.

Sources

  1. Isomorphic Labs
  2. Isomorphic Labs
  3. Isomorphic Labs

Related stories

Explore

More articles